{"title": "AstraZeneca's Calquence steps up to challenge Imbruvica with big CLL green light", "author": "Carly Helfand; Angus Liu", "url": "https://www.fiercepharma.com/marketing/astrazeneca-s-calquence-steps-up-to-challenge-imbruvica-big-cll-green-light", "hostname": "fiercepharma.com", "description": "Johnson & Johnson and AbbVie's Imbruvica has enjoyed a nice run in previously untreated chronic lymphocytic leukemia over the last few years. | Johnson & Johnson and AbbVie's Imbruvica has enjoyed a nice run in previously untreated chronic lymphocytic leukemia over the last few years. But major competition is here in the form of AstraZeneca's Calquence. Thursday, the FDA\u2014along with regulators in Canada and Australia\u2014green-lighted Calquence in newly diagnosed CLL or small lymphocytic lymphoma.", "sitename": "FiercePharma", "date": "2019-11-21", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}